- Global Pharma News & Resources

ORIC Pharmaceuticals to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 /PRNewswire/ -- ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on the discovery and development of novel therapies against treatment-resistant cancers, announced that Jacob Chacko, MD, Chief Executive Officer, will host one-on-one investor meetings on Wednesday, February 27 at the 8th Annual SVB Leerink Global Healthcare Conference, held Wednesday, February 27 through Friday, March 1, 2019 at the Lotte New York Palace in New York City.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor. ORIC's pipeline also includes an orally-available small molecule inhibitor of CD73, as well as other undisclosed programs targeting mechanisms of oncology therapy resistance. ORIC's scientific founders are Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering novel targets in cancer that have led to innovative treatments. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column GroupTopspin PartnersOrbiMedEcoR1, Fidelity, Foresite and others. ORIC is headquartered in South San Francisco, California.

For more information, please contact:

Krys Corbett


View original content:

SOURCE ORIC Pharmaceuticals

Editor Details

Last Updated: 20-Feb-2019